The present invention provides 3-{1-[5-chloro-2-(2-ethylbutoxy) benzyl]-5-methyl-1H-pyrazol-3-yl}propanoicacid in crystalline form. The present invention further provides methods for treating disorders associated with DP1, FP, TP, EP1 and EP4prostaglandin (PG) receptors such as allergic conditions, pain, gastrointestinal tract disorders or ocular hypertension.